Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) went down by -11.52% from its latest closing price compared to the recent 1-year high of $8.59. The company’s stock price has collected -10.51% of loss in the last five trading sessions. Press Release reported on 01/29/21 that Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
Is It Worth Investing in Catabasis Pharmaceuticals Inc. (NASDAQ :CATB) Right Now?
Plus, the 36-month beta value for CATB is at 1.80. Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for Catabasis Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $24.00. CATB currently public float of 17.47M and currently shorts hold a 6.47% ratio of that float. Today, the average trading volume of CATB was 10.07M shares.
CATB’s Market Performance
CATB stocks went down by -10.51% for the week, with a monthly jump of 14.96% and a quarterly performance of 131.62%, while its annual performance rate touched -42.41%. The volatility ratio for the week stands at 10.14% while the volatility levels for the past 30 days are set at 16.85% for Catabasis Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -3.76% for CATB stocks with a simple moving average of -34.61% for the last 200 days.
CATB Trading at 17.77% from the 50-Day Moving Average
After a stumble in the market that brought CATB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.33% of loss for the given period.
Volatility was left at 16.85%, however, over the last 30 days, the volatility rate increased by 10.14%, as shares surge +15.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.54% upper at present.
During the last 5 trading sessions, CATB fell by -10.51%, which changed the moving average for the period of 200-days by -47.06% in comparison to the 20-day moving average, which settled at $3.29. In addition, Catabasis Pharmaceuticals Inc. saw 47.20% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CATB
The total capital return value is set at -74.30, while invested capital returns managed to touch -73.35. Equity return is now at value -73.70, with -65.00 for asset returns.
Based on Catabasis Pharmaceuticals Inc. (CATB), the company’s capital structure generated 6.31 points at debt to equity in total, while total debt to capital is 5.93. Total debt to assets is 5.39, with long-term debt to equity ratio resting at 2.88. Finally, the long-term debt to capital ratio is 2.71.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.74.